Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds – Yahoo Finance

The new serotonin receptor model (5-HT2A) will allow the Company to rapidly increase drug analysis promoting near-term patent filings for novel psychedelic molecules.
DENVER, Jan. 10, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced today they have completed a target-based model of the classic psychedelic serotonin receptor 5-HT2A for use in their AI-driven drug discovery program. The new model will allow them to expeditiously screen billions of structures to determine which novel compounds are most likely to increase binding affinity, enabling them to continue creating improved second and third generation psychedelic molecules for medical use.

By centering their drug discovery efforts around artificial intelligence (AI) and machine learning (ML), Mydecine is positioned to discover drug enhancements more cost effectively and more efficiently than their competitors. Using AI technology is relatively new in the drug development space and its applications are continuously expanding. The goal of this technology is to eliminate, or drastically reduce, the manual efforts companies typically undergo to identify possible drug improvements. By filtering the drug candidates with AI, the Company is inherently making their investments in later stage drug development more valuable by eliminating potential candidates that are likely to fail early on in the process.
Without AI and ML, based on their hypotheses, companies have to manually synthesize each molecule and individually test the likelihood of a successful binding agent. This process can consume enormous amounts of time and money; therefore, efficiently eliminating candidates likely to fail in preference for candidates that are more promising is extremely valuable.
“AI gives us an incredibly robust tool for screening potential novel psychedelic compounds. This screening gives us increased confidence in investing in the later stages of our drug development and enables rapid development in our pipeline,” said Chief Science Officer Rob Roscow.
“Our 5-HT2A AI models construct billions of new drug candidates and filter them for their ability to modulate the 2A receptor activity. These AI models also predict the interactions and affinity of each drug candidate to the level of a single atom. By considering the unique structural and dynamical fingerprint of the 2A receptor, our AI drug discovery program paves the road towards designing selective 5-HT2A modulators which reduces any potential side effects that may emerge in the future,” said Khaled Barakat, Principal Investigator with Applied Pharmaceutical Innovation.
Mydecine has mainly focused on psilocybin, and its active metabolite psilocin, in their drug development efforts. When ingested, psilocin interacts with the human body’s serotonin receptor 5-HT2A triggering a “psychedelic experience” but perhaps more importantly, neuroplasticity. Neuroplasticity, the brain’s ability to reorganize its neural pathways to accomplish the needed outcome, is a critical component for successful psychedelic-assisted-psychotherapy.
Psilocybin/psilocin, as it stands in nature, poses a few challenges for successful integration for medical use such as its weak shelf stability and its wide variety of onset time between patients. Both of these characteristics must be improved upon in order to create medication-based treatments that are safe, effective and repeatable. Mydecine will use their AI 5-HT2A model to identify which molecules are most likely to bind to this receptor, enabling them to improve the undesirable characteristics of naturally produced psilocybin/psilocin.
This 5-HT2A receptor model is just the beginning of Mydecine’s planned modeling in production that will continue to enhance their AI-driven drug discovery program. The Company’s AI program has already led to identifying promising enhancements to psilocybin and psilocin which they have included in their recent patent application around MYCO-004, which directly addresses further precision in delivery control and shelf stabilization through a dermal route of administration. To learn more about the benefits of this second-generation psychedelic compound, read the Company’s recent press release here.
Read: 3 Things Investors Should Know About Mydecine’s Artificial Intelligence & Machine Learning Drug Discovery Program
About Mydecine Innovations Group
Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is a biotechnology and digital technology company developing innovative first-and-second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug development infrastructure. Mydecine Innovations Group was founded in 2020 on the guiding principle that there is a significant unmet need and lack of Innovations in the mental health and therapeutic treatment environments. Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction, and other mental health disorders. Mydecine Innovations Group's business model combines clinical trials and data outcome, technology, scientific and regulatory expertise with a focus on psychedelic therapy underpinned by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine Innovations Group aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way we treat mental health disorders. Mydecine Innovations Group's vision is to bridge the current gap between what the mental healthcare system currently provides with the needs of the patients. Mydecine Innovations Group is headquartered in Denver, Colorado, USA with international offices in Leiden, Netherlands.
Learn more at: www.mydecine.com and follow the company on Twitter, Instagram, and LinkedIn.
Sign up for Mydecine’s newsletter by scrolling to the bottom of this page.
Sign up for automatic email notifications when Mydecine publishes news here.
For more information, please contact:
Media Contact
Morgan Kervitsky, Director of Marketing
pr@mydecineinc.com
Investor Relations
Morgan Kervitsky, Director of Marketing
contact@mydecineinc.com
On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
contact@mydecineinc.com
For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.
This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management’s current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.

Braxia Scientific Corp. (the "Company" or "Braxia"), (CSE: BRAX) (FWB: 4960), a medical research company with clinics providing innovative psychedelic treatments for persons with depression and related disorders, is pleased to announce that it has closed its previously announced private placement of its common shares ("Common Shares") and warrants to purchase Common Shares ("Warrants") with institutional investors for gross proceeds of approximately CAD$3 million (the "Private Placement").
Monday was an up day for Novavax (NASDAQ: NVAX), one of the more volatile coronavirus stocks on the scene. Its shares rose by 6.5% on the back of some regulatory news in a major overseas market. On Monday morning, Novavax and manufacturer Serum Institute of India announced that an Emergency Use Authorization (EUA) submission had been filed with the South African Health Products Regulatory Agency (SAHPRA) for NVX-CoV2373, the company's coronavirus vaccine.
Shares of Moderna (NASDAQ: MRNA) climbed on Monday after the biotechnology leader said it could have a COVID-19 booster vaccine that specifically targets the omicron variant ready by the fall. As of 3:20 p.m. ET, Moderna's stock price was up more than 8%. CEO Stéphane Bancel said during an interview on CNBC that Moderna will soon begin clinical trials for its omicron-specific booster shot.
The world is anxiously waiting for more-effective weapons against the coronavirus, so it was little wonder that the stock of Molecular Partners (NASDAQ: MOLN) shot more than 30% higher on Monday. The German biotech, along with its partner Novartis (NYSE: NVS), had some potentially excellent news to report about their pipeline drug targeting the still-raging disease. Molecular Partners and Novartis announced that the initial part of a phase 2 clinical trial evaluating intravenous dosing of that drug, ensovibep, met its primary endpoint of viral load reduction.
Jenna Jameson was diagnosed with Guillain-Barré syndrome, a rare autoimmune disorder.
Pfizer is entering the CRISPR space through a $1.35 billion deal with Beam, the companies said Monday. But Beam stock fell in response.
In a high-stakes presentation at the J.P. Morgan Healthcare conference, Biogen Inc. executives said they wanted to "improve the community's understanding" of Aduhelm but left less than 10 minutes to answer questions from investors and attendees.
Shares of BioNTech (NASDAQ: BNTX) closed Monday's trading session 8.6% higher, lifted largely by two developments. First, on Monday, BioNTech announced a collaboration with Crescendo Biologics to develop immunotherapies for treating cancer and other diseases. Pfizer and BioNTech are again working together to develop the omicron-specific vaccine.
Experts have recommended upgrading to an N95 or KN95 mask as they offer better protection against omicron.
Thanks to the dual headwinds of sky-high inflation and the threat of rising interest rates, biopharmaceutical stocks appear poised for a turbulent 2022. Underscoring this point, investors have been dumping risky clinical and early commercial-stage biopharma stocks over the past several weeks in response to these closely intertwined macro variables. This year thus seems destined to be a bona fide "stock-picker's market" for biopharma investors.
The two companies will develop three treatments for genetic disease by correcting errors in our genes, using base-editing technology.
Bedford RNA firm Stoke Therapeutics Inc. has signed a collaboration agreement potentially worth nearly $1 billion with San Diego-based Acadia Pharmaceuticals Inc.
GlaxoSmithKline and partner Vir Biotechnology said Tuesday that the U.S. government will buy 600,000 doses of sotrovimab, an investigational monoclonal antibody for early COVID-19 treatment. The extra doses will be delivered in the first quarter of 2022 to the U.S., which has an option to purchase more in the second quarter. The companies now have total binding agreements for 1.7 million doses worldwide. Sotrovimab was granted emergency use authorization by the Food and Drug Administration in Ma
At-home rapid tests are taking on a larger role in our COVID-19 mitigation strategy. But there's some nuance to when they work best.
The new deal brings to 1 million the total number of doses of the therapy that the U.S. government has purchased, according to GlaxoSmithKline.
We all do, or at least try to do, little daily things that are good for our body and mind—especially at the start of a new year. Whether that means taking the stairs instead of the escalator, swapping white bread for whole wheat, or drawing ourselves a long evening bath to soak in, it feels good to make healthy choices throughout the day. But it turns out one thing you may have been doing might not be so good for you after all—in fact, it could lead to dementia down the line.Dementia, defined by
Dr. Scott Gottlieb said while East Coast cases are peaking, other parts of the country where the Omicron variant isn't as prevalent yet probably have a couple more weeks of the current surge.
Philadelphia cell therapy developer Carisma Therapeutics has entered into a research collaboration with Moderna that includes Carisma receiving an upfront payment of $45 million. Moderna (NASDAQ: MRNA) will also invest $35 million in Carisma in the form of a convertible note, and in return get options for up to 12 targets for potential cancer therapies. Under the partnership, the two companies will work together to discover, develop and commercialize potential cancer treatments.
The Centers for Medicare and Medicaid Services is set to release a draft ruling by Wednesday on whether Medicare will cover the Alzheimer's drug Aduhelm.
The Supreme Court on Monday issued a revised transcript of oral arguments over a Biden administration vaccine rule that clarified a statement Justice Neil Gorsuch made about the number of annual flu deaths.The original, uncorrected transcript quotes Gorsuch as saying he believes the flu kills "hundreds of thousands of people every year."This erroneous transcription prompted legions of tweets and at least one media report that tut-tutted Gorsuch…

source
Connect with Chris Hood, a digital strategist that can help you with AI.

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2022 AI Caosuo - Proudly powered by theme Octo